Norman, Oklahoma 73071

  • Moderate to Severe Chronic Plaque Psoriasis

Purpose:

This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.


Criteria:

Inclusion Criteria: - Patients who have a diagnosis of plaque-type psoriasis for at least 6 months. Exclusion Criteria: - Patients with hypersensitivity to ustekinumab or any of the product excipients.


NCT ID:

NCT04785326


Primary Contact:

Ji-Su Song
Phone: 82-2-920-8866
Email: songjs@donga.co.kr


Backup Contact:

N/A


Location Contact:

Norman, Oklahoma 73071
United States

Paul S Gillum
Phone: 405-329-0474

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: July 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.